1
|
Tuerkova A, Bongers BJ, Norinder U, Ungvári O, Székely V, Tarnovskiy A, Szakács G, Özvegy-Laczka C, van Westen GJP, Zdrazil B. Identifying Novel Inhibitors for Hepatic Organic Anion Transporting Polypeptides by Machine Learning-Based Virtual Screening. J Chem Inf Model 2022; 62:6323-6335. [PMID: 35274943 PMCID: PMC9795544 DOI: 10.1021/acs.jcim.1c01460] [Citation(s) in RCA: 9] [Impact Index Per Article: 4.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/07/2023]
Abstract
Integration of statistical learning methods with structure-based modeling approaches is a contemporary strategy to identify novel lead compounds in drug discovery. Hepatic organic anion transporting polypeptides (OATP1B1, OATP1B3, and OATP2B1) are classical off-targets, and it is well recognized that their ability to interfere with a wide range of chemically unrelated drugs, environmental chemicals, or food additives can lead to unwanted adverse effects like liver toxicity and drug-drug or drug-food interactions. Therefore, the identification of novel (tool) compounds for hepatic OATPs by virtual screening approaches and subsequent experimental validation is a major asset for elucidating structure-function relationships of (related) transporters: they enhance our understanding about molecular determinants and structural aspects of hepatic OATPs driving ligand binding and selectivity. In the present study, we performed a consensus virtual screening approach by using different types of machine learning models (proteochemometric models, conformal prediction models, and XGBoost models for hepatic OATPs), followed by molecular docking of preselected hits using previously established structural models for hepatic OATPs. Screening the diverse REAL drug-like set (Enamine) shows a comparable hit rate for OATP1B1 (36% actives) and OATP1B3 (32% actives), while the hit rate for OATP2B1 was even higher (66% actives). Percentage inhibition values for 44 selected compounds were determined using dedicated in vitro assays and guided the prioritization of several highly potent novel hepatic OATP inhibitors: six (strong) OATP2B1 inhibitors (IC50 values ranging from 0.04 to 6 μM), three OATP1B1 inhibitors (2.69 to 10 μM), and five OATP1B3 inhibitors (1.53 to 10 μM) were identified. Strikingly, two novel OATP2B1 inhibitors were uncovered (C7 and H5) which show high affinity (IC50 values: 40 nM and 390 nM) comparable to the recently described estrone-based inhibitor (IC50 = 41 nM). A molecularly detailed explanation for the observed differences in ligand binding to the three transporters is given by means of structural comparison of the detected binding sites and docking poses.
Collapse
Affiliation(s)
- Alzbeta Tuerkova
- Department
of Pharmaceutical Sciences, Division of Pharmaceutical Chemistry, University of Vienna, Althanstraße 14, A-1090 Vienna, Austria
| | - Brandon J. Bongers
- Division
of Drug Discovery and Safety, Leiden Academic Centre for Drug Research, Leiden University, P.O. Box 9502, 2300 RA Leiden, The Netherlands
| | - Ulf Norinder
- Department
of Pharmaceutical Biosciences, Uppsala University, Box 591, SE-75124 Uppsala, Sweden,MTM
Research Centre, School of Science and Technology, Örebro University, SE-70182 Örebro, Sweden
| | - Orsolya Ungvári
- Drug
Resistance Research Group, Institute of
Enzymology, RCNS, Eötvös Loránd Research Network, Magyar tudósok krt. 2, H-1117 Budapest, Hungary,Doctoral
School of Biology and Institute of Biology, ELTE Eötvös Loránd University, Pázmány P. stny. 1/C, H-1117 Budapest, Hungary
| | - Virág Székely
- Drug
Resistance Research Group, Institute of
Enzymology, RCNS, Eötvös Loránd Research Network, Magyar tudósok krt. 2, H-1117 Budapest, Hungary
| | | | - Gergely Szakács
- Drug
Resistance Research Group, Institute of
Enzymology, RCNS, Eötvös Loránd Research Network, Magyar tudósok krt. 2, H-1117 Budapest, Hungary,Department
of Medicine I, Institute of Cancer Research, Comprehensive Cancer
Center, Medical University of Vienna, A-1090 Vienna, Austria
| | - Csilla Özvegy-Laczka
- Drug
Resistance Research Group, Institute of
Enzymology, RCNS, Eötvös Loránd Research Network, Magyar tudósok krt. 2, H-1117 Budapest, Hungary
| | - Gerard J. P. van Westen
- Division
of Drug Discovery and Safety, Leiden Academic Centre for Drug Research, Leiden University, P.O. Box 9502, 2300 RA Leiden, The Netherlands,.
Phone: +31 71 527 3511
| | - Barbara Zdrazil
- Department
of Pharmaceutical Sciences, Division of Pharmaceutical Chemistry, University of Vienna, Althanstraße 14, A-1090 Vienna, Austria,. Phone: +43-1-4277- 55113
| |
Collapse
|
2
|
Ungvári O, Király L, Székely V, Poór M, Bakos É, Özvegy‐Laczka C. Pyranine‐based Dyes as a Sensitive Tool to Investigate Drug/Food Interactions of Organic Anion Transporting Polypeptides, OATP1B1/3 and OATP2B1. FASEB J 2021. [DOI: 10.1096/fasebj.2021.35.s1.05069] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
Affiliation(s)
- Orsolya Ungvári
- Institute of EnzymologyEötvös Loránd Research Network, Research Centre for Natural SciencesBudapest
| | - Laura Király
- Institute of EnzymologyEötvös Loránd Research Network, Research Centre for Natural SciencesBudapest
| | - Virág Székely
- Institute of EnzymologyEötvös Loránd Research Network, Research Centre for Natural SciencesBudapest
| | - Miklós Poór
- Department of PharmacologyUniversity of PécsFaculty of PharmacyPécs
| | - Éva Bakos
- Institute of EnzymologyEötvös Loránd Research Network, Research Centre for Natural SciencesBudapest
| | - Csilla Özvegy‐Laczka
- Institute of EnzymologyEötvös Loránd Research Network, Research Centre for Natural SciencesBudapest
| |
Collapse
|
3
|
Tupova L, Hirschmugl B, Sucha S, Pilarova V, Székely V, Bakos É, Novakova L, Özvegy-Laczka C, Wadsack C, Ceckova M. Interplay of drug transporters P-glycoprotein (MDR1), MRP1, OATP1A2 and OATP1B3 in passage of maraviroc across human placenta. Biomed Pharmacother 2020; 129:110506. [PMID: 32768979 DOI: 10.1016/j.biopha.2020.110506] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/02/2020] [Revised: 06/27/2020] [Accepted: 07/02/2020] [Indexed: 12/16/2022] Open
Abstract
Special attention is required when pharmacological treatment is indicated for a pregnant woman. P-glycoprotein (MDR1) is a well-known transporter localized in the maternal blood-facing apical membrane of placental syncytiotrophoblast and is considered to play an important role in protecting the developing fetus. Maraviroc, a MDR1 substrate that is registered for treatment of HIV infection, shows a low toxicity profile, suggesting favorable tolerability also if administered to pregnant women. Nevertheless, there is only poor understanding to date regarding the extent to which it permeates across the placental barrier and what are the transport mechanisms involved. Endeavoring to clarify the passage of maraviroc across placenta, we used in this study the method of closed-circuit perfusion of maraviroc across human placental cotyledon. The data obtained confirmed slight involvement of MDR1, but they also suggest possible interaction with other transport system(s) working in the opposite direction from that of MDR1. Complementary in vitro studies, including cellular experiments on choriocarcinoma BeWo cells as well as transporter-overexpressing MDCKII and A431 cell lines and accumulation in placental fresh villous fragments, revealed maraviroc transport by MRP1, OATP1A2, and OATP1B3 transporters. Based on mRNA expression data in the placental tissue, isolated trophoblasts, and fetal endothelial cells, especially MRP1 and OATP1A2 seem to play a crucial role in cooperatively driving maraviroc into placental tissue. By the example of maraviroc, we show here the important interplay of transporters in placental drug handling and its possibility to overcome the MDR1-mediated efflux.
Collapse
Affiliation(s)
- Lenka Tupova
- Charles University, Faculty of Pharmacy in Hradec Kralove, Department of Pharmacology and Toxicology, Akademika Heyrovskeho 1203, Hradec Kralove, Czech Republic
| | - Birgit Hirschmugl
- Medical University of Graz, Department of Obstetrics and Gynecology, 8036, Graz, Austria
| | - Simona Sucha
- Charles University, Faculty of Pharmacy in Hradec Kralove, Department of Pharmacology and Toxicology, Akademika Heyrovskeho 1203, Hradec Kralove, Czech Republic
| | - Veronika Pilarova
- Charles University, Faculty of Pharmacy in Hradec Kralove, Department of Analytical Chemistry, Akademika Heyrovskeho 1203, Hradec Kralove, Czech Republic
| | - Virág Székely
- Membrane Protein Research Group, Institute of Enzymology, Research Centre for Natural Sciences, Magyar tudósok krt. 2., H-1117, Budapest, Hungary
| | - Éva Bakos
- Membrane Protein Research Group, Institute of Enzymology, Research Centre for Natural Sciences, Magyar tudósok krt. 2., H-1117, Budapest, Hungary
| | - Lucie Novakova
- Charles University, Faculty of Pharmacy in Hradec Kralove, Department of Analytical Chemistry, Akademika Heyrovskeho 1203, Hradec Kralove, Czech Republic
| | - Csilla Özvegy-Laczka
- Membrane Protein Research Group, Institute of Enzymology, Research Centre for Natural Sciences, Magyar tudósok krt. 2., H-1117, Budapest, Hungary
| | - Christian Wadsack
- Medical University of Graz, Department of Obstetrics and Gynecology, 8036, Graz, Austria
| | - Martina Ceckova
- Charles University, Faculty of Pharmacy in Hradec Kralove, Department of Pharmacology and Toxicology, Akademika Heyrovskeho 1203, Hradec Kralove, Czech Republic.
| |
Collapse
|
4
|
Székely V, Patik I, Ungvári O, Telbisz Á, Szakács G, Bakos É, Özvegy-Laczka C. Fluorescent probes for the dual investigation of MRP2 and OATP1B1 function and drug interactions. Eur J Pharm Sci 2020; 151:105395. [PMID: 32473861 DOI: 10.1016/j.ejps.2020.105395] [Citation(s) in RCA: 11] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/06/2019] [Revised: 04/27/2020] [Accepted: 05/25/2020] [Indexed: 12/16/2022]
Abstract
Detoxification in hepatocytes is a strictly controlled process, in which the governed action of membrane transporters involved in the uptake and efflux of potentially dangerous molecules has a crucial role. Major transporters of hepatic clearance belong to the ABC (ATP Binding Cassette) and Solute Carrier (SLC) protein families. Organic anion-transporting polypeptide OATP1B1 (encoded by the SLCO1B1 gene) is exclusively expressed in the sinusoidal membrane of hepatocytes, where it mediates the cellular uptake of bile acids, bilirubin, and also that of various drugs. The removal of toxic molecules from hepatocytes to the bile is accomplished by several ABC transporters, including P-glycoprotein (ABCB1), MRP2 (ABCC2) and BCRP (ABCG2). Owing to their pharmacological relevance, monitoring drug interaction with OATP1B1/3 and ABC proteins is recommended. Our aim was to assess the interaction of recently identified fluorescent OATP substrates (various dyes used in cell viability assays, pyranine, Cascade Blue hydrazide (CB) and sulforhodamine 101 (SR101)) (Bakos et al., 2019; Patik et al., 2018) with MRP2 and ABCG2 in order to find fluorescent probes for the simultaneous characterization of both uptake and efflux processes. Transport by MRP2 and ABCG2 was investigated in inside-out membrane vesicles (IOVs) allowing a fast screen of the transport of membrane impermeable substrates by efflux transporters. Next, transcellular transport of shared OATP and ABC transporter substrate dyes was evaluated in MDCKII cells co-expressing OATP1B1 and MRP2 or ABCG2. Our results indicate that pyranine is a general substrate of OATP1B1, OATP1B3 and OATP2B1, and we find that the dye Live/Dead Violet and CB are good tools to investigate ABCG2 function in IOVs. Besides their suitability for MRP2 functional tests in the IOV setup, pyranine, CB and SR101 are the first dual probes that can be used to simultaneously measure OATP1B1 and MRP2 function in polarized cells by a fluorescent method.
Collapse
Affiliation(s)
- Virág Székely
- Membrane protein research group, Institute of Enzymology, Research Centre for Natural Sciences, H-1117 Budapest, Hungary; Doctoral School of Molecular Medicine, Semmelweis University, H-1085 Budapest, Hungary
| | - Izabel Patik
- Membrane protein research group, Institute of Enzymology, Research Centre for Natural Sciences, H-1117 Budapest, Hungary
| | - Orsolya Ungvári
- Membrane protein research group, Institute of Enzymology, Research Centre for Natural Sciences, H-1117 Budapest, Hungary
| | - Ágnes Telbisz
- Biomembrane research group, Institute of Enzymology, RCNS, H-1117 Budapest, Hungary
| | - Gergely Szakács
- Membrane protein research group, Institute of Enzymology, Research Centre for Natural Sciences, H-1117 Budapest, Hungary; Institute of Cancer Research, Medical University Vienna, Borschkegasse 8a, 1090 Wien, Austria
| | - Éva Bakos
- Membrane protein research group, Institute of Enzymology, Research Centre for Natural Sciences, H-1117 Budapest, Hungary
| | - Csilla Özvegy-Laczka
- Membrane protein research group, Institute of Enzymology, Research Centre for Natural Sciences, H-1117 Budapest, Hungary.
| |
Collapse
|